Average Ratings 0 Ratings

Total
ease
features
design
support

No User Reviews. Be the first to provide a review:

Write a Review

Average Ratings 0 Ratings

Total
ease
features
design
support

No User Reviews. Be the first to provide a review:

Write a Review

Description

BetterLetter AI serves as a cutting-edge generative writing platform that leverages artificial intelligence to assist users in crafting effective and personalized text for various business communications, including sales outreach, cold emails, follow-ups, and LinkedIn messages, by transforming simple prompts into refined, persuasive content within moments. The platform empowers users to articulate their objectives, target audience, and essential messages, automatically generating professional drafts that can be tailored for tone, style, and individual personalization, thereby streamlining the process of engaging potential clients and enhancing outreach efforts. It excels at large-scale personalization by enabling the integration of recipient-specific information and context, ensuring that each message feels uniquely crafted, regardless of how many contacts are being reached out to, while also offering features for templates, rewriting, and summarizing to enhance or modify existing text. The user-friendly interface of BetterLetter AI allows for rapid iteration on drafts, adjustments to language for better clarity and impact, and seamless exporting of the final versions to various email applications or CRM systems. Additionally, this tool is designed to facilitate effective communication strategies that can significantly improve response rates and customer engagement.

Description

Introducing a versatile API designed to seamlessly integrate with your diabetes management system, offering tailored therapeutic education and enhanced insights into blood glucose level fluctuations. This solution enables real-time risk predictions, fostering greater personalization and improved system regulation, while adeptly managing complex living scenarios characterized by rapid glucose variations. With advancements in telemedicine and retrospective analysis, patients receive robust decision-support tools. Currently, Hillo is developing the next iterations of its AI technology, which includes a therapeutic recommendation system aimed at preventing hypoglycemia and hyperglycemia, anticipated to achieve CE mark class IIB by 2020. Additionally, a new generation of the artificial pancreas is projected for release in 2021, addressing key limitations of existing systems through ultra-personalization driven by machine learning. This innovative approach marks the introduction of the first self-learning artificial intelligence capable of predicting blood glucose levels, aiming to secure a CE mark as a medical device, thereby transforming diabetes management for users. In essence, Hillo's advancements could significantly enhance the quality of life for individuals managing diabetes.

API Access

Has API

API Access

Has API

Screenshots View All

Screenshots View All

Integrations

No details available.

Integrations

No details available.

Pricing Details

$10.22 per month
Free Trial
Free Version

Pricing Details

No price information available.
Free Trial
Free Version

Deployment

Web-Based
On-Premises
iPhone App
iPad App
Android App
Windows
Mac
Linux
Chromebook

Deployment

Web-Based
On-Premises
iPhone App
iPad App
Android App
Windows
Mac
Linux
Chromebook

Customer Support

Business Hours
Live Rep (24/7)
Online Support

Customer Support

Business Hours
Live Rep (24/7)
Online Support

Types of Training

Training Docs
Webinars
Live Training (Online)
In Person

Types of Training

Training Docs
Webinars
Live Training (Online)
In Person

Vendor Details

Company Name

BetterLetter

Country

United Kingdom

Website

betterletter.ai/

Vendor Details

Company Name

Hillo

Country

France

Website

www.hillo.ai/

Product Features

Product Features

Alternatives

Alternatives

Werd Reviews

Werd

Artificial General Intelligence Company
Altis Labs Nota Reviews

Altis Labs Nota

Altis Labs